4.2 Article

Replicated evidence for aminoacylase 3 and nephrin gene variations to predict antihypertensive drug responses

期刊

PHARMACOGENOMICS
卷 18, 期 5, 页码 445-458

出版社

FUTURE MEDICINE LTD
DOI: 10.2217/pgs-2016-0204

关键词

aminoacylase 3; atenolol; bisoprolol; genome-wide; hypertension; losartan; nephrin; pharmacogenomics

资金

  1. Sigrid Juselius Foundation
  2. Finnish Foundation for Cardiovascular Research
  3. Blueprint Genetics, Inc.
  4. Metabolon, Inc.

向作者/读者索取更多资源

Aim To replicate the genome-wide associations of the antihypertensive effects of bisoprolol and losartan in GENRES, using the Finnish patients of LIFE study. Patients & methods: We analyzed association of four SNPs with atenolol and three SNPs with losartan response in 927 Finnish LIFE patients (467 for atenolol and 460 for losartan). Results: rs2514036, a variation at a transcription start site of ACY3, was associated with blood pressure response to atenolol in men in LIFE. Response to bisoprolol was correlated to baseline plasma levels of N-acetylphenylalanine and phenylalanine (ACY3 substrate and end product, respectively) in GENRES study. NPHS1 variation rs3814995 was associated with losartan effect in LIFE. Conclusion: We provide support for two pharmacogenomic markers for beta-blockers and angiotensin receptor antagonists.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据